2022 World Conference on Lung Cancer (ePosters)-EP06.01-010. Clinical Outcomes after Hypo Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer During The Covid-19 Pandemic In Morocco

EP06.01-010. Clinical Outcomes after Hypo Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer During The Covid-19 Pandemic In Morocco

Back to course

Pdf Summary

This retrospective report examines the outcomes of patients with locally advanced non-small cell lung cancer who underwent Hypo fractionated radiotherapy during the COVID-19 pandemic in the Greater Casablanca Region, Morocco. The aim of the study was to assess the impact of radiotherapy and chemotherapy adaptations on survival and toxicity for these patients.<br /><br />The study included adult patients with inoperable or unresectable locally advanced non-small cell lung cancer who were treated with Hypo fractionated radiotherapy between April 2020 and April 2021. The primary endpoint was local control, and overall survival, metastasis-free survival, and toxicity rates were also analyzed.<br /><br />The results showed that the 6-month, 12-month, and 18-month overall survival rates were 100%, 88%, and 48% respectively. The median survival rate for all stages was 17.5 months, with adenocarcinomas having a slightly better median survival than squamous cell carcinomas. The most common sites of metastases were the lung, bone, brain, and liver. The incidence of grade III-V toxicities was low, with only grade I/II radiation pneumonitis occurring in 4% of patients.<br /><br />Overall, the study found that the COVID-19 pandemic led to changes in patient treatment, including an increase in hypofractionation. The analysis aimed to provide insights into the outcomes of patients treated during the pandemic and assess the effects of treatment adaptations on survival and toxicity.<br /><br />In conclusion, this study highlights the importance of adapting treatment approaches during the COVID-19 pandemic to minimize risks for patients with locally advanced non-small cell lung cancer. The findings suggest that Hypo fractionated radiotherapy, along with chemotherapy adaptations, can achieve favorable outcomes in terms of survival and toxicity rates.

Asset Subtitle

Meriem cherkaoui

Meta Tag

Speaker Meriem cherkaoui

Topic Management of Lung Cancer in the Era of COVID-29

Keywords

retrospective report

locally advanced non-small cell lung cancer

Hypo fractionated radiotherapy

COVID-19 pandemic

survival and toxicity

metastases

grade III-V toxicities

adenocarcinomas

squamous cell carcinomas

treatment adaptations